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Abstract
The controversy about the use of data from human volunteer studies involving experimental exposure to pesti-
cides as part of regulatory risk assessment has been widely discussed, but the complex and interrelated scientific
and ethical issues remain largely unresolved. This discussion paper, generated by authors who comprised a work-
group of the ICOH Scientific Committee on Rural Health, reviews the use of human experimental studies in regula-
tory risk assessment for pesticides with a view to advancing the debate as to when, if ever, such studies might be
ethically justifiable. The discussion is based on three elements: (a) a review of discussion papers on the topic of
human testing of pesticides and the positions adopted by regulatory agencies in developed countries; (b) an ana-
lysis of published and unpublished studies involving human testing with pesticides, both in the peer-reviewed lit-
erature and in the JMPR database; and (c) application of an ethical analysis to the problem. The paper identifies
areas of agreement which include general principles that may provide a starting point on which to base criteria for
judgements as to the ethical acceptability of such studies. However, the paper also highlights ongoing unresolved
differences of opinion inherent in ethical analysis of contentious issues, which we propose should form a starting
point for further debate and the development of guidelines to achieve better resolution of this matter.
Introduction
In recent years, there has been considerable controversy
about the scientific value and ethical acceptability of stu-
dies involving experimental exposure of human volun-
teers to low doses of pesticides [1-12]. Although such
studies have been conducted for many decades, albeit
on a limited scale, the controversy around their use has
been prompted particularly by more recent debates on
the use of data from human volunteer studies to inform
regulatory risk assessment [13,14].
This issue emerged in the public domain as a result of
changes in the regulatory framework in the United
States through the Food Quality Protection Act [15] and
the subsequent submission of data from experimental
volunteer studies to support the setting of toxicological
reference values for certain pesticides [16-20]. The sub-
sequent debate has led to a critical examination of the
use of human data in general, and its use in pesticide
regulation in both the USA and the European Union
and in the deliberations of the FAO/WHO Joint Meet-
ing on Pesticide Residues (JMPR).
In contrast to many other chemicals, regulatory
assessment of risks to human health from pesticides is
typically based on a wide set of studies in vitro and in
vivo in animals, sometimes supplemented by observa-
tional studies (primarily epidemiological investigations
though sometimes case reports and case series may be
used) in humans. Animal studies examine both kinetics
(absorption, distribution, metabolism and excretion,
ADME studies) and toxic effects. A final outcome of
many toxicity studies is the identification of No
Observed Adverse Effect Levels (NOAELs) and Lowest
Observed Adverse Effect Levels (LOAELs), which are
used to derive various toxicological reference values. It
is customary to include uncertainty factors (also known
as safety or assessment factors) to account for individual
variability and uncertainties in extrapolation to humans,
and sometimes also to allow for limitations of experi-
mental design. A default value of 100 is frequently used,
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for possible interspecies differences and one to reflect
human inter-individual variability. The resulting refer-
ence value represents the maximum exposure to the
pesticide or its metabolites in specified circumstances
(e.g. daily dietary consumption over the course of a life-
time, systemic exposure each day over the course of
each spraying season, year on year) that the risk assessor
is confident would not be expected to produce adverse
health effects in even the most sensitive individual.
T h eu s eo fu n c e r t a i n t yf a c t o r st oc o m p e n s a t ef o r
interspecies and intra-species variability, including that
related to possible vulnerable sub-populations (e.g.
infants and children), therefore addresses degrees of
uncertainty in the risk assessment. There is also the
important consideration of choosing the appropriate
species when extrapolating to humans. Using experi-
mental human data has been argued to reduce uncer-
tainty in the risk assessment and to obviate partially the
requirement to use uncertainty factors. However, this
has raised many ethical questions, principally because of
possible risks to the participants from the experimental
exposure, and whether the reduced uncertainty justifies
t h ed e l i b e r a t ee x p o s u r eo fh u m a n st on o n - t h e r a p e u t i c
agents [12].
In the context of increasing global attention to ethical
oversight of biomedical research [21-23], this paper sets
out to explore the ethical issues involved in such stu-
dies. The complex and inter-related scientific and ethical
questions challenge the international community of
occupational health professionals to provide guidance
on such matters. This is particularly important since
many developing countries (and even some developed
countries) rely on regulatory standards derived from the
regulatory risk assessment processes in the USA and
Europe without applying their own procedures.
Thus, the specific objectives of this review were to
examine experience of the use of human experimental
studies in regulatory risk assessment, and to identify key
areas of ethical disagreement in debates on the topic,
with a view to informing policy decisions. As would be
expected, it is not always feasible to achieve consensus;
hence this review aims to highlight areas both of agree-
ment and of disagreement, in order to foster debate on
this important issue.
Methods
Scope: For this review, experimental exposure was
defined as intentional exposure of a study participant to
one or more pesticides, to an extent that would not
have occurred had the individual not participated in a
study. The review excluded observational studies in
which the investigator did not attempt to modify sub-
jects’ exposures in any way, experimental studies in
which the intervention was aimed only at reducing
exposures to pesticides, and experiments in which non-
toxic marker substances were used as a proxy for pesti-
cides (e.g. to assess levels and determinants of exposure
in spraying operations). The review was further limited
to studies in which there was no therapeutic or prophy-
lactic objective (e.g. excluding studies to evaluate inter-
ventions aimed at controlling vectors for human
diseases).
Three approaches were used in this review
Firstly, a literature review was conducted directed at
three categories of reports: a) discussion papers on
human testing of pesticides; b) position papers from
governments, regulatory agencies and civil society stake-
holders; c) examples of studies which involved human
volunteers exposed to pesticides. Searches in the peer-
reviewed literature were conducted independently by
three members of the workgroup and results pooled.
The definition outlined above of experimental exposure
to pesticides without a therapeutic or prophylactic
objective served as the inclusion criterion. Keywords
used in the primary search included: “pesticide/s,” AND
“ethics,” AND “experiments” (or “experimental studies”).
Secondary searches were done introducing “exploitation”
as a substitute for “ethical” and “risk assessment” for
“research”. References cited in articles suggesting human
volunteer studies were also followed up. This strategy
yielded 27 empirical studies.
Additionally, position papers were sought opportunis-
tically, through contacts and experience of Workgroup
members, one of whom had been a member of the Joint
FAO/WHO Meetings on Pesticide Residues (JMPR) sev-
eral times. Also, studies reviewed by the JMPR were
identified by two Group members through examination
of its reports from 1997 to 2006. A further 10 peer
reviewed papers involving experimental exposure of
humans to pesticides were identified through the JMPR
reports, yielding a total of 37 empirical studies involving
human volunteer exposure in the peer reviewed
literature.
Secondly, these 37 empirical studies involving human
volunteer exposure identified from the peer-reviewed lit-
erature were reviewed for the following variables: study
purpose; whether the study was explicitly addressed at
pesticide authorization procedures; whether there was
evidence of ethical committee approval; compounds (or
groups of compounds); and main characteristics of the
experimental design (route, dose - single or repeated,
dose level(s), number of groups and number of subjects
per group). Studies were categorized as either addressing
absorption, distribution, metabolism and excretion
(ADME studies); biological effects and/or toxicity; expo-
sure; or other. It was possible to allocate a particular
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available, the assessor was asked to comment on the sta-
tistical power of the study, on apparent compliance of
the study with ethical standards and whether the study
was instrumental in waiving, either totally or partially,
the uncertainty factor related to interspecies extrapola-
tion in setting reference values, therefore allowing for
higher reference values than would be set based only on
animal studies. Lastly, the assessor, based on his toxico-
logical knowledge, commented on whether the study
was necessary to obtain the required information, recog-
nizing that such an evaluation required value judgments.
The data abstraction tool is contained in additional file
1. Sampling for this analysis was conducted with the
intention of obtaining a picture of the range of the types
of studies in the published literature involving experi-
mental exposure of humans to pesticides to inform ethi-
cal analysis rather than seeking representivity of the
population of such studies.
Thirdly, an ethical analysis was applied to the argu-
ments identified from the literature. In approaching
the ethical analysis, cognizance was taken of the
numerous codes providing guidance for health profes-
sionals in relation to biomedical research, particularly,
the World Medical Association (WMA) Declaration of
Helsinki [24], and ethical codes of the WHO-CIOMS
[21] and the International Commission on Occupa-
tional Health [22].
Although the Declaration of Helsinki specifically
addresses medical research, its basic principles have
become the cornerstone of ethical analysis of any health
research study involving human subjects. These princi-
ples include the primacy of the well-being of the
research subject, the need for the research to conform
to accepted scientific principles, review and approval of
the study protocol by a research ethics committee, the
need for an assessment of the risk to the individual and
the community in comparison with the expected bene-
fits, and free consent of the research subject on the
basis of full information about these risks and benefits
of participation.
Review Findings
W eb e g i nb ys u m m a r i s i n gt h ec u r r e n tr e g u l a t o r yp o s i -
tions of the USEPA, the JMPR and the EU. We next
present the results of our review of empirical studies
that have involved deliberate human exposure to pesti-
cides, examining the uses which have been made of
human experimental data in risk assessment for pesti-
cides. We then provide a general ethical analysis of the
issues involved, including problems that arise in relation
to use of data from experimental studies conducted in
the past as opposed to those that might be undertaken
in the future.
Positions of regulatory agencies on the use of data from
experimental human exposure to pesticides
The United State Environmental Protection Agency
In the USA, the Food Quality Protection Act of 1996
introduced the concept of an additional uncertainty fac-
tor of up to 10 into the risk assessment process for pes-
ticides, to account for possible increased sensitivity of
infants and children [25]. A number of dosing studies
with volunteers were subsequently submitted to the
agency with the intent of providing human data which
would not require application of the normal inter-spe-
cies uncertainty factor. This resulted in a protracted and
intensely polarized debate. Some scientists and activist
groups challenged the ethical and scientific validity of
the studies, contending among other things that people
should not be put at risk for the purpose of reducing
the stringency of regulatory standards [3,6,8,11,12].
Other scientists and industry groups argued that the
human dosing studies were needed to ensure the scien-
tific quality and accuracy of EPA’s safety evaluations and
that they had been and could be conducted ethically
[4,5,10,26,27]. In response to the controversy, EPA com-
missioned the National Academy of Sciences to advise
whether and under what circumstances the Agency
should consider and accept intentional human dosing
studies. The National Research Council committee
recommended that such studies should be conducted
and considered for regulatory purposes only if all of a
set of specified conditions were met that related to both
scientific validity and ethical standards (see appendix
below) [28]:
On the basis of this advice EPA issued a final rule in
2006, which established the framework under which
data from intentional human dosing studies would be
considered in future [25]. The rule details the many dif-
ficult questions with which the Agency had to struggle,
and the reasons for its decision. The final rule categori-
cally prohibited any EPA-funded research, or the consid-
eration of other (’third party’) research involving
‘intentional’ exposure of pregnant women and children.
It also extended the Federal policy that governs protec-
tion of human subjects in research (’Common Rule’)t o
other ‘intentional’ exposure studies involving non-preg-
nant adults intended to be submitted to EPA under the
pesticide laws. Furthermore, it required protocols for
such studies to be submitted to EPA before the research
was started, and it established an independent Human
Studies Review Board to review new research proposals
and research reports intended to contribute to decision-
making.
However, the EPA rule does not prohibit studies
w h e r et h e r ew a sn oa bi n i t i oi n t e n t i o nt ou s et h ed a t a
for regulatory risk assessment, or where the study was
initially conducted outside the ambit of the US
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part of the regulatory process, the rule indicates that the
EPA will consider accepting such data “unless there is
clear and convincing evidence that it was fundamentally
unethical or significantly deficient with respect to the
ethical standards prevailing when the research was con-
ducted.” The EPA position is therefore not to exclude
human studies from consideration in the regulatory risk
assessment process, but to set conditions under which
such studies might be considered.
The Joint FAO/WHO Meeting on Pesticide Residues (JMPR)
The Joint FAO/WHO Meeting on Pesticide Residues
(JMPR) has several times addressed the issue of studies
in human volunteers [29-31]. It has always been recog-
nised that “human data from accidental or deliberate
poisonings, biomarker monitoring studies, epidemiology
studies, volunteer studies, and clinical trials on the same
or structurally similar compounds can provide useful
data to help establish” reference doses [31]. In addition,
h u m a nd a t ao nap e s t i c i d e“should always be evaluated
even when they are not used to derive” a reference
value [30]. While recognising that the use of data from
human volunteers in chemical risk assessment is a con-
troversial issue, the JMPR underlined that “the use of
such data can reduce the level of uncertainty inherent in
extrapolating from animal models” [31]. During its
meetings the JMPR pointed out the need to consider
both ethical (particularly the relevant components of the
Helsinki Declaration) [29] and scientific issues, particu-
l a r l yi n v o l v i n gt h eq u a l i t ya n di n t e g r i t yo ft h ed a t aa n d
the adequacy of the documentation of methods (includ-
ing statistics and control values) [28]. It was stressed
that the conduct and use of studies in humans “should
always be considered in the context of the overall toxi-
cological database” [31]. For instance, ARfDs based on
studies in humans should provide a sufficient margin of
safety for toxicological endpoints that cannot readily be
addressed by such studies (e.g. developmental toxicity or
carcinogenicity). By saying this, the JMPR implied that
the conduct of studies in humans is only permitted after
the whole toxicological database in animals has been
developed and understood. Only after the relevant toxi-
cological effects (end-points) have been identified, could
a study in human volunteers be considered for its scien-
tific relevance as a component of its ethical
appropriateness.
The scientific criteria included, besides those generally
applicable to studies in animals: a) group size in relation
to factors such as inter-individual variation in response
and the level of change considered not to be adverse, b)
reference to the IPCS Guidance for the use of chemical-
specific adjustment factors [32] of a minimum group
size of 56 or smaller if e.g. combining results from two
or more dose levels or applying an increased uncertainty
factor; c) the fact that the critical end-points identified
in animal studies can be investigated appropriately in
human studies, d) the relevance of sex differences in
toxicity. In addition the JMPR [28] indicated that “stu-
dies that have not been performed in accordance with
ethical principles but are scientifically valid should be
used only if the findings indicate that acceptable human
exposure is lower than the level that would be deter-
mined without the use of such a study”.
The European Union (EU)
In Europe, the regulatory framework concerning author-
isation and use of pesticides has been very recently
changed with the approval of Regulation 1007/2009 of
21 October 2009 that replaces Council Directive 91/
414/EEC of 15 July 1991 on the placing of plant protec-
tion products (PPP) on the market and all its subse-
quent amendments. The Regulation firmly states that
“In relation to human health, no data collected on
humans shall be used to lower the safety margins result-
ing from tests or studies on animals” (art. 4, point 6).
Therefore, it appears that, while recognising that data
on the effects of human exposure are valuable, EU pol-
icy has taken the view that their usefulness is to confirm
the validity of estimations made based on extrapolation
from the full toxicological database regarding target
organs, dose-response relationships, and the reversibility
of toxic effects [33] and to ‘provide reassurance on the
extrapolation process’ [34] without direct effects on the
definition of reference values.
This was also expressed in the latest draft guidance
document on the setting and application of acceptable
operator exposure levels (AOEL) that precludes the use
of studies conducted in humans for the purpose of
determining a human No Observed Adverse Effect Level
for an active substance to derive regulatory limit values,
confirming their role as solely supplementary to extra-
polations from appropriate studies in laboratory model
species [35]. Only if human study data suggest that
h u m a n sa r em o r es e n s i t i v e( w h i c hw o u l di m p l yan e e d
to set a lower AOEL value) would these data take prece-
dence over animal data. No such provision has been
made for the reverse case (i.e. human data showing
decreased sensitivity, allowing a higher AOEL value), a
position criticized by the European Food Safety Author-
ity’s Panel on Plant Protection products and their Resi-
dues (PPR), who have argued that data from human
volunteer studies should be used to derive reference
values, if the studies were ethically and scientifically
valid [36]. In reaching this view, the PPR Panel noted
limitations of studies conducted in humans including
small sample sizes, lack of sex-specific data and the pos-
sibility of studying only selected end-points. The PPR
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context of the entire toxicological profile of the PPP
under consideration.’
Review of experimental studies involving human
exposure to pesticides
Studies published in peer-reviewed journals
Thirty-seven (37) papers, published in peer reviewed
journals in the period 1947 - 2006 that met the inclu-
sion criteria [37-73], were evaluated (See Table 1). The
compounds or chemical groups addressed were: organo-
phosphate compounds (18 papers), phenoxy herbicides
(4 papers), phenol derivative fungicides (3 papers), pyre-
thrins or pyrethroids and piperonyl butoxide (4 papers),
atrazine, captan, diethylphenylacetamide and analogs,
lindane and warfarin (one paper each). Seventeen of
these papers were published in the decade 1990-1999,
fifteen before 1990 and six since 2000. The most com-
mon aim was to assess the ADME of one or more pesti-
cides (28 studies) and less commonly biological effects
and/or toxicity (14 studies), mostly before 1990, or
exposure levels (4 studies). Three studies involved other
aims (e.g. estimating exposure via foliar residues; evalu-
ating effects specific to particular anatomic sites, and
studying the interaction between two active ingredients),
and 8 of the 37 studies had more than one aim. None
of the papers explicitly addressed or stated an intention
to address authorization or regulatory issues, although
at least two, and perhaps a third study, did contribute to
the setting of reference values by indicating a need to
adjust an uncertainty factor. The two studies contribut-
ing directly to setting reference values included a study
published in 1977 involving 5 participants exposed to
2.4D [65] and a study involving 5 participants per group
exposed to mevinphos for 30 days [63].
In 15 papers the route of administration was dermal,
in 14 oral, in four oral and dermal and in one each it
was inhalation, dermal and inhalation, dermal and intra-
v e n o u s ,d e r m a la n do r a l ,a n do r a l .O n eo ft h ep a p e r s
described a field study. Eleven studies were based on
repeated doses, and 22 on single doses. For the field
study, dosing was not applicable. The number of expo-
sure groups ranged from one to four, but one or two
were the options more frequently followed. The number
of subjects per group ranged from 1 to 21, but in 22
studies the number was lower than 10. The statistical
power of the study was rated as acceptable in 14 cases
and weak in 19 cases. In 22 cases the study was
reported to have been approved by an ethics committee,
whilst in the other studies the approval of an ethics
committee was not requested or it was not possible to
establish whether ethical approval had been sought or
obtained. Nineteen studies were considered by the eva-
luator to comply with the Common Rule requirements,
but in the remaining 15 it was not possible to answer
this question. Nineteen of the evaluated studies col-
lected information that was not obtainable in other
ways, while in 7 cases the need for the study was uncer-
tain. It should be noted that in one of the oldest studies
evaluated, the experimental design was such that “severe
poisonings” occurred in two of the studied subjects, in
one subject on two occasions and in the second subject
on three [52].
Studies to assess dose-response relationships for early
markers of toxicity with examples
The opposing viewpoints with regard to studies underta-
ken for the purpose of determining a NOAEL are high-
lighted in an exchange of correspondence triggered by
Sass and Needleman [3] who cited two studies sub-
mitted as part of the process of setting regulatory refer-
ence values in the US. In the first study [74], involving 6
exposed and 3 control subjects (all men), exposed parti-
cipants ingested daily oral doses of dichlorvos at a level
of approximately 0.1 mg/kg/day and had blood samples
drawn every two to three days for measurement of ery-
throcyte cholinesterase activity. On the basis of an
absence of a statistically significant difference, the
authors concluded that a NOAEL could be established
at 0.1 mg/kg/day. However, Sass and Needleman
pointed out that there were, in fact, identified in the
report, statistically significant differences in cholinester-
ase depression at 7, 11, 14, 16 and 18 days that were
regarded by the researchers as biologically insignificant.
The critique further pointed out that the lack of power
in the study would invalidate any inferences for or
against a NOAEL. In response, Chart and colleagues [4]
disputed the biological significance of the modest choli-
nesterase decline since a) no clinical effects were seen
and b) the decline was said to provide evidence of expo-
sure, but was too small to indicate hazard. With regard
to the power issue, Chart et al acknowledged the rela-
tively small study size, but pointed to an overall data-
base of hundreds of animal and human studies with
dichlorvos, arguing that the available health data on any
given substance should be evaluated as a whole in risk
assessments.
The second study criticised by Sass and Needleman
[3] was conducted by Wyld et al [75] and involved a
randomized, single oral dose, double-blind placebo con-
trolled trial of aldicarb administration, involving 24 men
and 12 women, who received doses of aldicarb at three
concentrations (0.01, 0.05 and 0.075 mg/kg) and a
group of 22 controls (16 men and 6 women). Sass and
Needleman took issue with the fact that a wide range of
adverse effects (total of 24 symptoms) were reported,
but that only one was considered to be treatment-
related. They also pointed out that there was a signifi-
cant decline in erythrocyte cholinesterase at all dose
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Authors Study
type*
Compound/Chemical
Group
Route Statistical
Power
Details on Ethics
Committee Approval
Higher
Reference
1. Bartels et al, 1998 [37] A Phenols Dermal n.a. Yes No
2. Buchholz et al, 1999
[38]
A Atrazine Dermal Weak Yes No
3. Cnubben et al, 2002
[39]
Phenols Dermal and
Intravenous
n.a. Yes No
4. Dick et al, 1997 [46] A OC Dermal Acceptable Yes No
5. DuBois and Mangun,
1947 [47]
T OP Oral Weak Not provided No
6. Edson et al, 1967 [48] T OP Oral Acceptable Not provided No
7. Flannigan et al, 1985
[49]
T Permethrin Dermal Acceptable Yes No
8. Griffin et al, 1999 [50] A OP Oral and Dermal Weak Yes No
9. Guthrie et al, 1976 [51] A, O OP Field study Weak Not provided No
10. Hayes et al, 1964 [52] A, T, E OP Dermal and
Ingestion
n.a. Not provided No
11. Kezic et, 1996 [53] A Dichloro-propene Dermal n.a. Yes No
12. Krieger et al, 1993
[54]
A Captan Dermal Weak Not provided No
13. Meaklim et al, 2003
[55]
A, T OP Oral Weak Yes Yes
14. Meuling et al 2005
[56]
A OP Dermal Weak Yes No
15. Moeller et al, 1962
[57]
T OP Oral Acceptable Not provided No
16. Moody et al 1992 [58] A, E, O Phenoxy herbicides Oral Weak Yes No
17. Moody et al, 1990
[59]
A Phenoxy Herbicides Dermal Weak Yes No
18. Nolan et al, 1984a
[60]
A, T OP Oral and Dermal Weak Not provided No
19. Nolan et al, 1984b
[61]
A OP Oral and Dermal Acceptable Yes No
20. Ramsey et al 1992
[45]
A Fluazifop-butyl Herbicide Dermal Acceptable Yes No
21. Rao et al, 1979 [62] T OP Ingestion Weak Not provided No
22. Rider et al, 1975 [63] T OP Oral Acceptable Not provided Yes
23. Roy et al, 2006 [40] A, T, E N,N-diethyl-m-toluamide and
permethrin
Dermal Weak Yes No
24. Sanderson and Edson,
1964 [64]
T OP Oral Weak Not provided No
25. Sauerhoff et al, 1977
[65]
A Phenoxy Herbicide Oral n.a. Not provided No
26. Selim et al, 1999 [66] A 2,4-D Oral Weak Not provided Partly
27. Selim et al, 1995 [67] A Piperonyl butoxide Dermal Weak Yes No
28. Timchalk et al, 1998
[68]
A Phenols Dermal Weak Yes No
29. Verberk et al, 1977
[69]
T OP Oral Acceptable Not provided No
30. Verberk, 1977 [70] T OP Oral Acceptable Not provided No
31. Vessell et al, 1975 [71] A, E, O Warfarin (rodenticide) Oral Acceptable Not provided No
32. Wester et al, 1993 [72] A OP Dermal Acceptable Not provided No
33. Wester et al, 1994 [73] A Pyrethrin and piperonyl
butoxide
Dermal Weak Yes No
34. Wilks et al. 1993 [41] A Herbicide Oral Acceptable Yes No
35. Williams et al, 2004
[44]
A OP Dermal Acceptable Yes No
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no “treatment-related clinical symptoms” were present
at doses of 0.05 mg/kg or less conflicted with a pre-
viously reported Californian food poisoning incident
[76], in which this dose was sufficient to necessitate hos-
pitalisation. In response, [27] Tobia et al (2004) argued
that almost half of the symptoms were in the placebo
group, others were temporally unrelated, or were symp-
toms inconsistent with cholinesterase depression. They
also disputed the NOEL of 0.05 mg/kg, arguing that the
case reports cited by Goldman et al (1990) [76] con-
tained insufficient data to derive an exposure estimate.
They argued it was precisely the uncertainty over the
validity of the case report data that prompted the
human volunteer study, and that its findings were con-
sistent with the rest of the aldicarb database.
Studies to assess human exposures when applying
pesticides
Of the studies identified from the peer-reviewed pub-
lished literature, only 4 were studies that evaluated
exposures under experimental conditions, all of which
examined dermal uptake of a pesticide. At least one
study [40] was a pilot investigation that was part of a
larger trial to examine interactions between various
compounds used to protect armed forces against disease
vectors and chemical warfare agents, and was not
intended to contribute to regulatory risk assessment.
None was deemed to have adequate power and none
had evidence of approval by an independent ethics
committee.
Studies to assess absorption, distribution, metabolism and
excretion (ADME) of pesticides in humans
Of the studies identified for review from the peer-
reviewed published literature, by far the majority (n =
28) were ADME studies and, of these, the majority (17)
addressed questions that could not be answered without
an experimental design. Ethical approval could be con-
firmed in slightly more than half of the studies (n = 22),
and acceptable power calculations were evident for
about half of the studies in which they were relevant for
the design.
Human ADME studies have two main purposes. The
first is the identification of metabolic pathways and tar-
get metabolites, which can subsequently be used in bio-
logical monitoring studies in the workplace or in the
general population. Secondly, in order to interpret the
results of biological monitoring studies and extrapolate
back from the excretion of a metabolite to exposure to
the parent compound, detailed knowledge about the
human pharmacokinetics of the compound is required.
The best guide to interpretation of biological monitoring
studies is therefore a controlled human volunteer study,
usually with a single oral dose of the compound of
interest [41], although it may be desirable to study more
than one dose level, and, where dermal or inhalation
uptake is important, more than one route of administra-
tion. Improvements in analytical methodology enable
such studies to be carried out with very low doses,
improving the margins of safety for volunteers, particu-
larly when compared to acute animal studies. ADME
studies may also be important to establish whether a cri-
tical metabolic pathway occurs in humans, and thereby
inform a decision about a reference value based on that
pathway.
As is the case with studies of exposure, there may be
circumstances in which the required information on
ADME in humans can be obtained through observa-
tional studies in operators during routine use of a pesti-
cide. However, this will not be possible for agents not
yet approved for distribution, or where an experimental
study is expected to generate new information that will
materially enhance the risk assessment. Examples where
ADME studies have contributed to improving under-
standing of, and opportunities to control risks, include
the following:
A study of cypermethrin metabolism amongst volun-
teers who received a single oral and dermal dose [42]
was able to demonstrate different metabolite patterns
depending on the exposure route. Improved assessment
of the amount absorbed across the skin in a field worker
exposure study [41]was made possible by inclusion of a
broader range of metabolites, illustrating that route-spe-
cific metabolism of cypermethrin, which may not have
been predicted from animal studies, could be established
from a human volunteer study.
A second example involved the rice herbicide molinate
[41]. This study showed that the major urinary metabo-
lite of molinate in human volunteers was very different
from that found in rat studies. This striking species dif-
ference indicated that, in the absence of data from
human volunteer studies, an extrapolation from rat data
would underestimate the absorbed dose in field studies
by a factor of 30 if the incorrect metabolite was used as
a marker.
Table 1 A profile of 37 human volunteer studies in the peer-reviewed literature (Continued)
36. Woollen et al, 1991
[43]
A Fluazifop-butyl herbicide Oral Weak Yes No
37. Woollen et al, 1992
[42]
A Pyrethroid Insecticide Oral and Dermal Acceptable Yes No
* A = ADME study; T = Toxicity endpoint; E = Exposure study; O = Other
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fluazifop-butyl (FB), a post-emergence herbicide used to
control grass weeds in a large variety of broad-leaved
crops. A human volunteer study to measure excretion of
the acid metabolite of FB confirmed that between 80%
and 93% of the dose was excreted in urine as fluazifop
acid over a period of 6 days in a one-compartment
model [43]. The presence of an accurate biomarker con-
tributed to other studies’ ability to characterize worker
exposure and demonstrate the beneficial effects of wear-
ing gloves during mixing and loading [45,77].
The JMPR database
In reviewing the JMPR database (Table 2) it was evident
that experimental data involving human volunteers were
more commonly used to set reference values than was
the case in studies published in the peer-reviewed litera-
ture. Of the 150 active ingredients evaluated by the
JMPR from 1996 to 2006, experimental data involving
human volunteers were used in risk assessment for 32
of these substances. Most of the compounds were choli-
nesterase inhibitors (19 OPs and 3 carbamates). These
studies were used to set both the ARfD and the ADI for
6 compounds and the ARfD for another 7 compounds,
and, with the exception of one ADI and one ARfD, they
were all cholinesterase inhibitors. In total, therefore,
about 40% of those JMPR evaluations which considered
experimental data from human volunteer studies used
the data to set reference values.
In the case of OPs and carbamates, the studies in
volunteers have been used when there was evidence that
no critical effect other than inhibition of acetylcholines-
terase was observed in animals treated with the com-
pound. For instance, because of possible carcinogenic
effects of carbaryl or toxicity to reproduction of
dimethoate, the ADI for these compounds was based on
such effects in animals, giving a value lower than the
one that would have been derived from human data. In
one instance (diazinon), the data in humans were not
used because the study was performed only in males
and the data in animals showed a relevant sex difference
in sensitivity. Some of the studies that were used to set
the reference values were performed in the seventies,
and although no formal GLP (good laboratory practice)
standards were available at that time, these studies were
considered acceptable “according to the standard” of the
time.
In three studies, involving amitraz, oxamyl and metho-
myl, clinical signs were observed in the volunteers. In
the cases of the carbamates (oxamyl and methomyl)
these took the form of a moderate increase of salivation
after oral treatment with the highest of the three doses
used. This finding was reported as probably due to a
local effect of the compounds since it was neither asso-
ciated with other typical cholinergic signs nor with a
level of RBC AChE inhibition that would indicate a cho-
linergic syndrome. In the case of amitraz, signs of neu-
rotoxicity were observed in two subjects receiving 0.25
mg/kg bw during an ADME study. Details of the study
were not available; however, it is noted that the dose
was 1-2 orders of magnitude lower than that which
caused neurotoxicity in several animal species, including
baboons.
Seven studies included assessment of the toxicoki-
netics of the compound. In the case of acephate and
methamidophos, the ADME data helped in reducing the
uncertainty of the assessment and contributed to a par-
tial waiving of the factors used to take account of uncer-
tainty in setting a reference value.
It should be noted that studies in humans were gener-
ally considered of the highest value by JMPR, and gener-
ally took precedence over the data from animals. Even
when the number of volunteers was relatively low (e.g.:
N = 5-8), animal data were used simply to support the
data in humans, rather than vice-versa.
Four studies were discarded by JMPR, either because
of poor reporting, which included the impossibility of
assessing the ethical standards, or because of methodo-
logical problems such as analytical methods being no
longer acceptable by modern standards, or an insuffi-
cient number of subjects. These studies were generally
conducted in the 1960s and ‘70s.
Three studies were performed to assess the potential
for skin sensitisation. These studies, although not affect-
ing the setting of reference values, may have had some
impact during the authorisation processes in regulatory
settings outside the JMPR.
Ten of the JMPR studies were also published in peer-
reviewed journals. Four of these studies contributed to
t h ed e f i n i t i o no ft h eA D Io rA R f D( f o rc h l o r p y r i f o sa n d
mevinphos), but only one (mevinphos) was directly used
to set the value. The paper on chlorpyrifos was also
available as a full study report from the company. The
other studies were not used because of deficiencies of
the study (n = 2), because they were performed to assess
skin irritation properties (n = 1) and because they did
not address toxicological end-points relevant for setting
an ADI or ARfD (n = 4).
In summary, it appears that experimental studies
involving human volunteers that are published in the
scientific peer-reviewed literature have not been expli-
citly performed with the purpose of helping to set refer-
ence values. Most of the recent studies in this category
deal with ADME rather than with toxic effects. How-
ever, studies submitted to the JMPR evaluation process
are more likely to be directed at toxicity endpoints and
less likely to appear in the peer-reviewed literature. This
means that studies with toxicity endpoints appear less
likely to be subject to peer review and accompanying
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Compound Group Year Number of
toxicity
studies
Number of
ADME
studies
Used
for
ADI
Used
for
ARfD
Comments
Carbaryl Carb-
amate
1996 3 1 (same study) NO NO Carcinogenicity in mice
Dimethoate OP 1996 1 (1967) NO NO Reproductive toxicity
Mevinphos OP 1996 2 (1975) YES YES SF of 20 because N = 8
Fenthion OP 1997 1 (1979) YES (in
1995)
NO Not suitable for ARfD because no effects in rats after
a single much higher dose
Malathion OP 1997 1 (1962) NO NO Old study, possibly containing impurities, NOAEL in
rats much higher
Methidathion OP 1997 1 (1970) NA YES SF of 10 despite N = 8 because supported by data in
rats with a SF of 100
Amitraz 1998 3 (1984) 1 (1984) (same
study)
NA YES
Dichloran 1998 1 (1962) NO NA Supportive of data in dogs with a SF of 200 because of
data gaps
Chlorpyrifos OP 1999 7 (1971-1999) 1 (1999) (same
study)
YES YES ADI based on data in animals with a SF of 100 and in
humans with a SF of 10 (N = 4-6) giving the same ADI
Ethoprophos OP 1999 1 (1986) 1 (1986, same
study)
NA NA Study performed to assess occupational exposure
Permethrin Pyre-throid 1999 1 (1985) NO NA
Fenitrothion OP 2000 3 (1968-1999) 1 (1999) (same
study)
NO YES Too short duration (4 days) for setting the ADI
Imazalil Azole 2000 1 (1979) NO NA Skin irritation study
Diazinon OP 2001 2 (1999) NA NO Only in male and studies in animals showed sex difference
Methomyl Carbamate 2001 1 (1998) YES YES SF of 5 because of rapid reversibility of effects, used
although N = 5 because supported by data in animals
Acephate OP 2002 2 (1972-2000) 1 (2000) (same
study)
NO NO Not used because brain AChE more sensitive to
inhibition than RBC AChE
Ethephon 2002 3 (1971-1977) NA YES
Methamidophos OP 2002 2 (1973) NO NO Studies considered supportive (giving similar ADI or ARfD)
Oxamyl Carb-
amate
2002 1 (1999) YES YES Although N = 5, data in animals were supportive
Oxydemeton
methyl
OP 2002 2 (1973) NA NO Not used because of methodological problems
Tolylfluanid Sulf-amide
fun-gicide
2002 1 (1968) NA NA Skin irritation study
Triazophos OP 2002 4 (1971-1973) YES YES N = 5-25, acceptable because performed according to the
standard of the time
Malathion OP 2003 1 (2000) 1 (2000) (same
study)
NA YES N = 14
Paraquat 2003 1 (1984) NO NO Poor skin absorption
Phospmet OP 2003 1 (1999) NA YES N = 12
Propiconazole Azole 2004 1 (1991 NA NA Study for skin sensitisation
Acephate OP 2005 2 (2000-2003) 2 (2000-2003)
(same studies)
YES YES N = 7-14, more data on brain vs RBC AChE allowed t
he use of human data. Comparative metabolism data also
allowed the use of a chemical specific assessment factor
Pirimiphos-
methyl
OP 2006 2 (1974-1976) NA NO Considered supportive since it would have given
a slightly lower ARfD
Temephos OP 2006 1 (1967) NA NO Poor quality of reporting
Thiabedazole Azole 2006 1 (1965) NO NO Relevant parameters could not be assessed in humans
* Note: malathion and acephate have been evaluated twice
AChE = Acetyl Cholinesterase
ADME = Absorption, Distribution, Metabolism and Excretion
ADI = Acceptable Daily Intake
ARfD = Acute Reference Dose
NOAEL = No Observed Adverse Effect Level
RBC = Red Blood Cell
SF = Safety Factor
London et al. Environmental Health 2010, 9:50
http://www.ehjournal.net/content/9/1/50
Page 9 of 17ethical oversight (except as part of regulatory evalua-
tion). Further, in none of the studies reviewed, in either
the peer-reviewed literature or the JMPR database, was
it evident that the human data contributed to a lower
(more stringent) reference value than that based on ani-
mal data; rather, the converse was true - human data, if
they influenced a reference value at all, led to a relaxa-
tion of the value.
Ethical Analysis
Ethical analysis requires a structured approach to identi-
fying all issues relevant to judgments about the research
in question, particularly related to the expected and
unexpected consequences and to the relative balance of
burdens and benefits from participation in a research
study [78-80]. Additionally, particular concerns regard-
ing the capability of research participants, who are in a
dependent position in relation to the researcher, to
make informed decisions regarding their participation,
would be another key issue in this analysis. Here we
present a summary of an ethical analysis applied to
human volunteer studies involving experimental expo-
sure to pesticides, although a more detailed ethical ana-
lysis of the issues related to use of data from human
volunteer studies is contained in Additional File 2, with
detailed mapping of the issues for each stakeholder
identified.
In experimental human volunteer studies, study parti-
cipants are asked to carry a burden of potential adverse
effects because of their exposure to the pesticide(s)
under investigation without the possibility of personal
benefit. The risks to participants are substantially
reduced by taking into account all prior knowledge on
the toxicity of the compound in question, good study
design and careful monitoring of participants. But they
cannot be completely eliminated with absolute certainty.
The risk of toxicity will depend upon: a) the margin
between the experimental dose of the pesticide and the
lowest dose at which adverse effects might be expected
from prior knowledge; and b) the confidence that can
be placed in this prior knowledge. Whilst study design
aims to minimise the risk of toxicity, there are concerns
that unexpected effects may be impossible to predict
[6,11,12].
Informed consent is therefore essential to protect the
autonomy of participants, particularly where overt or
covert pressures exist, or where scientific uncertainty
about risk requires interpretation for a prospective parti-
cipant whose health literacy and familiarity with scienti-
fic concepts is low. This would be aggravated in
circumstances where research participants are drawn
from vulnerable populations, such as inmates of institu-
tions, mentally ill or cognitively handicapped, people
with limited language proficiency (for example, migrant
and seasonal workers) and even subjects who are eco-
nomically or educationally disadvantaged. Moreover,
informed consent would be a necessary but not suffi-
cient requirement for ethical approval of an experimen-
tal human volunteer study, since, in the absence of a
demonstrably favourable risk-benefit ratio, achieving
informed consent would, of itself, not provide ethical
justification for a study.
Further, payment issues complicate ethical assessment.
Volunteers who take part in experimental studies of pes-
ticides may be offered direct payment or a benefit in
kind for their participation. Payments to participants in
excess of their immediate direct costs (such as travel or
compensation for time off work) may be viewed in
many domains as undue inducements to participate
[81]. At the very least, planned compensation to
research subjects (monetary and otherwise, e.g. social
benefits, medical examinations) must be openly reported
in the oversight process required for ethical approval. In
the absence of payment, participants’ only reward is the
possible satisfaction of having helped to advance scienti-
fic knowledge for the benefit of others.
Other parties to the research will, by definition, have
different interests in the research proceeding. The study
investigators may benefit through the intellectual satis-
faction, publications and enhanced reputation arising
from the research, as well as materially through pay-
ment. Payments, whether the source is academic institu-
tions, public bodies or industry, may present threats to
the researcher’s independence if conflicts of interests are
not properly managed.
The pesticide manufacturer stands to gain where a
human experiment results in a risk assessment that
enables its product to be registered, or re-registered or
released more speedily to market. In general, a company
would only commission such a study where it expected
to gain financially as a long-term consequence, particu-
larly given the high costs of mounting such studies.
Users of pesticides may benefit from access to an effec-
tive means of controlling pest problems using an agent
that has less uncertainty in its risk assessment, or from
identification of methods for biomarker monitoring.
This may have positive effects in protecting workers’
health in agricultural enterprises, and in providing more
options for agricultural food production and public
health vector control. In theory, human volunteer stu-
dies may also help to prevent a use that would carry
unacceptable risks to operators, although no empirical
evidence of such an impact was found in our review.
In summary, where the study design permits the gen-
eration of meaningful data, most stakeholders other
than participants will either benefit or not be adversely
affected from the additional information. The critical
issue, therefore, is the balance between the benefits for
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health of study participants. These competing considera-
tions are inter-related in that the total risk will be
greater if more subjects take part in a study, but the
value of the information produced by the investigation
will be greater with a larger sample size. This applies
particularly to studies using toxicological endpoints.
A further ethical concern relates to whether pre-exist-
ing data from past human experiments, which could
assist in improving risk assessment, should be used in
assessing and managing the risks from pesticides, parti-
cularly in the situation where historical studies were car-
ried out under conditions which would not be
considered ethically acceptable by current standards.
The benefits from use of the data may be clear, and
there is no further disadvantage to the study participants
since their risk of adverse effects is past. There may,
however, be a societal harm, since use of data derived
from unethical experiments could impinge adversely on
core societal values.
Even if the study in question was considered ethically
acceptable at the time it was conducted, an ethical
assessment of its current use would need to take
account of the full spectrum of ethical issues, including
a critical assessment of both the potential benefits and
any adverse impacts on human dignity. Rather than
applying a general rule, such instances should be
addressed on a case-by-case basis
Discussion
The Helsinki Declaration [24] indicates clearly that “... in
medical research on human subjects, considerations
related to the well-being of the human subject should
take precedence over the interests of science and
society.” At face value, the Declaration prioritises the
safety and rights of study participants ahead of the inter-
ests of other stakeholders. While different articles in the
Declaration have to be interpreted in the context of all
other articles in the declaration, including, for example
recognition that “progress in the medical field is based
on research which ultimately must rest on experimenta-
tion involving human research subjects”, the protection
of participants from exploitation in research lies at the
heart of most ethical codes. Thus, in the risk-benefit
estimation, the evidence of protection of third parties
from risks from which they would otherwise not be pro-
tected, or of wider preventive benefits for society, is also
critical to ethical assessment.
There are consequences of experimental human
volunteer studies that can be considered to confer
health benefits on parties other than the study partici-
pants. For example, having data that confirm a biomar-
ker for a new pesticide might enable future monitoring
of workers or the planning of field epidemiological
studies with better exposure assessment, and better
understanding of the ADME for a pesticide may indicate
ways to improve control of exposure, or exclude certain
pathways as critical for toxic effects, thereby informing
risk assessment. It would appear, however, that the
quantum of benefit declines relative to the risk when
toxicity endpoints such as NOAELs are the object of the
study. This is particularly problematic if there is a lack
of study power, a common problem in NOAEL studies,
as confirmed in our review. It is therefore less obvious
how reducing uncertainty in risk assessment will, of
itself, lead to reduced risks to humans As would be
expected given the conservative assessment factors that
are applied in extrapolation from animals to humans,
none of the studies reviewed in this project that have
used human volunteer data, have resulted in lower
exposure limits to date. They have only confirmed exist-
ing values or, in a few cases, increased reference values.
The presumption of minimal risk is key to ethical
consideration. To have any confidence in ‘low-doses’
being well below levels of toxicity, we rely on animal
toxicity data, so experimental human volunteer studies
would only be feasible for chemicals with extensive ani-
mal databases. But, given the fact that we may not have
all information on all possible risks, some chronic out-
comes may occur at concentrations lower than those at
which other recognised effects occur. For example, by
analogy, there is experimental evidence that Chlorpyrifos
exerts neurodevelopmental impacts at lower concentra-
tions than would be needed to impact on cholinesterase
function [82] and similar findings have been made in
relation to other orgranophosphates [83-85]. While it is
possible that such effects may be judged irrelevant for
single dose studies in adults, it is nevertheless important
that the whole existing database is taken into account
when making judgments on the risk to volunteers, as
elaborated further below.
Resnik and Porter (2005) [10] deal with this in relation
to carcinogens by proposing that pesticides that are pos-
sible carcinogens should be excluded from any experi-
mental human volunteer studies (although this begs the
question of how a “possible carcinogen” should be
defined). They also propose that the burden of proof of
minimal risk be shifted onto the researcher to demon-
strate that the effects sought are not serious and are
reversible and suggest there should be long-term follow
up of study participants to monitor for adverse out-
comes. To some extent, their proposals mimic the gen-
eral requirement for ethical review which must identify
the appropriate balance between a credible or demon-
strable benefit and the risks involved. Insistence on
long-term follow-up of study participants could itself
only be recommended where it was considered ethically
justifiable - i.e. where there was sufficient prospect of
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time and privacy from the follow-up process. Moreover,
long-term follow up may not, of itself, be sufficient to
ensure avoidance of any long-term unanticipated harms.
Furthermore, some of the debates on experimental
human volunteer studies suggest that symptoms such as
headache, sweating and nausea, are “not serious and are
reversible” so would constitute minimal risk. But, given,
for example, a view that neurobehavioural symptoms are
part of a spectrum of neurotoxicity [86], such symptoms
may, however, also be markers of more profound
damage to the CNS and their prognostic significance
would need to be evaluated as part of the risk-benefit
assessment.
Lastly, much unease with the idea of permitting
human experimental volunteer studies rests with the
concern that this will be a slippery slope, which will, on
the one hand, encourage less than ethical studies in
countries where there are not established oversight
structures, and, on the other hand, justify arguments for
very low dosing of volunteers with other well recognised
toxins and toxicants such as lead if improvements of
preventive action or health protection were envisaged.
This remained a disputed issue within the Workgroup’s
discussions.
Based on the above considerations, the workgroup
could not reach a uniform position on whether experi-
mental human volunteer studies involving pesticides
should be permitted or prohibited. The issues represent
complex scientific and ethical challenges and their
assessment entails personal value judgements.
Points of Agreement
However, we do propose that the following general prin-
ciples may provide a starting point on which to base
judgements as to the ethics of such studies.
￿ Uncertainty in risk assessment for pesticides is
undesirable, as is harm or risk of harm to study par-
ticipants. Harm or risk of harm to a study partici-
pant is less unacceptable where the participant
derives a compensatory benefit in health or well-
being.
￿ Disparities in the apportionment of harms, risks
and benefits (e.g. a substantial risk and little benefit
to study participants with a substantial benefit and
little or no risk to other people) are undesirable.
￿ It must be mandatory that participants in research
involving experimental exposure to pesticides give
free and properly informed consent. This implies
that subjects whose capacity to give informed con-
sent is compromised should not be involved.
￿ Independent ethical review of experimental studies
in humans must be mandatory.
We therefore propose that the following criteria must
be considered in deciding whether a study involving
experimental exposure of humans to pesticides can be
scientifically and ethically justified:
1) Experimental studies in humans should be consid-
ered if (a) they will provide data that cannot be
obtained by other methods - i.e. there is cogent evi-
dence that there is there no other practical way to
get the information needed that does not involve
deliberate human exposure to pesticides; and (b) the
information to be obtained is needed to address the
optimal protection of health or prevention of illness;
and (c) the study has been designed in a manner
which ensures that its conduct, analysis and report-
ing will be adequate scientifically to answer the
question(s) at hand.
2) Pesticides areag r o u po fc h e m i c a l sw i t hav e r y
large toxicological database in animals, larger than
that for most other chemicals, and experimental stu-
dies in human volunteers should only be performed
after consideration of all relevant toxicological and
epidemiological data. Experimental exposure of
humans to pesticides should not be permitted in the
absence of an adequate prior toxicological database.
Further, the onus should be placed on the researcher
to provide evidence based on extensive animal and,
where appropriate, in vitro testing, that no adverse
effects are likely in study participants.
In addition, data from experimental studies of poten-
tial adverse effects in humans should only be used to
set reference values if it is clear from the toxicologi-
cal database that a) the chosen endpoint is both
appropriate and sensitive, and b) there are no other
toxicological effects seen in animal studies for which
there would be inadequate margins of exposure if
the human data were used.
3) Consideration of risks relative to benefits estab-
lishes that there is minimal risk to participants rela-
tive to potential benefits from the study, and that
the societal benefits of the study should substantially
outweigh any expected risks to participants.
4) All of the recognized ethical standards and proce-
dures for protecting the interests of study partici-
pants are observed, implying equitable standards of
benefit-risk assessment and rigorous informed con-
sent procedures. This should include full explana-
tion of the current knowledge and uncertainty
around the hazards of the agent/s and the risks of
exposure. Payment of volunteers for their participa-
tion beyond the immediate costs that they incur
could constitute an undue inducement in the con-
text of no evident therapeutic benefit and needs
careful examination.
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component of ethical requirements for a study, it
does not alone comprise sufficient grounds to render
a study ethical. Rather, in a stepwise approach to
ethical assessment, the first action is to determine
whether the study meets the risk-benefit threshold
before considering whether the requirement for
proper informed consent is also met. It would be
incorrect to focus alone on questions of informed
consent in these studies without a comprehensive
consideration of all aspects of their ethics.
6) No studies should be conducted without prior
assessment and approval by an ethics committee
that is independent of both the researcher and the
sponsors of the study. The review system should
place the onus on the researchers to provide an ethi-
cal analysis and ethical justification for his/her study
to the reviewing ethics committee as part of ethical
oversight. As a check and balance on ethical con-
duct, this measure is critically dependent on the
capacity of such ethics committees, which may vary
widely between different countries and contexts, as
well as the institutional environment that ensures
their independence. Without properly constituted,
adequately resourced and consciously independent
Ethics Committees, with the requisite skills-mix for
scientific and ethical assessment, this proviso may be
ineffective in ensuring adequate ethical protections
for studies of human exposure to pesticides. It is
also particularly important that this provision apply
regardless of country or region in the world, given
the potential for serious global inequalities in
research oversight.
7) The ethics of using findings from past studies
involving experimental human exposure to pesticides
should be considered on a case-by-case basis.
These above seven points of agreement concur with
ethical guidelines for epidemiological studies published
by CIOMS in 2009 [80].
Points of Disagreement
Whilst agreement within the authors was possible for
the above recommendations, areas of dispute that could
not be resolved included the following:
1) Many criticisms of studies entailing experimental
exposure of human volunteers to pesticides have
focused on their use to reduce the need for uncer-
tainty factors in regulatory risk assessments. The
workgroup were divided over whether this was rele-
vant to ethical analysis. One view held that use of
data from experimental volunteer studies to set
reference values when the studies were not
appropriately designed for this purpose (and were
perhaps conducted for other reasons), was a scienti-
fic problem rather than an ethical issue. It should
also be taken into account that the setting of refer-
ence values is most often decided by others than the
researchers involved. An alternative view was
t h a tt h eu s eo fs t u d yd a t as h o u l da l w a y sb ei n t e g r a l
to consideration of the ethics of a study at the
outset, and so was not separable from ethical
considerations.
2) One view regarded research intended to help
relieve industry of a regulatory burden as not repre-
senting a societal but rather a private benefit, con-
sideration of which is integral to the assessment of
the relative burdens and benefits of the research.
Further, research presented as having a different
endpoint (e.g. an ADME study) but actually intended
for the purpose of facilitating a waiver of an uncer-
tainty factor, or discounting of a toxic effect as not
relevant to humans, should not be allowed to alter
reference values upward so as to avoid use of experi-
mental human volunteer studies as a strategy to sub-
vert stricter regulatory standards. A counter
argument was that unnecessarily strict controls on
one pesticide may lead to use of alternative products
that in fact carry a higher risk. In this argument,
provided the risks from participation in an ADME
study are sufficiently small, their use for the purpose
of facilitating a waiver of an uncertainty factor to
allow ongoing use of a pesticide could be acceptable.
3) Related to the above, is the question of how to
identify and quantify potential societal benefits from
such studies. There was disagreement on the extent
to which potential benefits of improved risk assess-
ment for pesticides could be linked to potential ben-
efits such as reducing unsafe use of pesticides,
avoiding substitution by more hazardous methods of
pest control, reducing hazards from vector-borne
disease and improving food availability and security.
The more distal the causal attribution of benefits,
the more contested claims to benefits are likely to
be. For example, arguing for better food availability
on the basis of human testing presupposed a very
long set of assumptions, which stray very far from
the science and ethics of human testing studies.
4) The group also differed with regard to the nature
of benefits related to data to inform more cost-effec-
tive regulation, or reducing the costs of regulation.
One view held that, unless they demonstrated a
need for protective measures which had earlier not
been known, studies aimed at providing more cost-
effective regulation, or simply reducing the cost of
regulation, would not meet the criterion for benefit
and therefore could not be justified in relation to the
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tect participants, as has been argued elsewhere [12].
An alternative view in the workgroup was that such
studies should be examined and reviewed following
the principles of balancing benefits and risks, the
ascertainment of an informed consent procedure
and an independent assessment by an independent
ethical review board or its equivalent. One formula-
tion of such a weighing up of risks and benefits
might be to say that intentional human dosing stu-
dies that are to be used only to improve the accu-
racy of a reference dose (RfD), and that otherwise
provide no health or environmental benefit, can be
justified only when there is reasonable certainty that
participants will experience no adverse effects.
5) There was also disagreement related to estima-
tions of minimal risk. One perspective took the view
that if an adequate animal toxicology database on
the chemical existed, the risks of long-term effects
from appropriately low experimental exposures
could be trusted to be negligible. Within the group,
however, there was concern about how easy it was
to assume such low risk, particularly with repeat
exposures in some study designs.
6) Additionally, the group considered but was
divided over a further criterion - whether there
should be an absolute proscription on human studies
involving pesticides that are genotoxic or that have
effects that are not easily predictable with simple
dose-response relationship, such as might be the
case for some endocrine disrupting chemicals. One
view argued that no studies should be permitted
with such agents, or at the very least, they should be
exceptional based on cogent motivation. Another
view was more permissive and did not automatically
exclude studies with such chemicals, but rather pro-
posed that they should be evaluated on a case-by-
case basis, again with careful consideration of the
risk-benefit analysis.
7) There was also considerable discussion within the
group over the question of scientific independence
in relation to the source of the funding and the
affiliations of the researchers, and its relevance to
ethical considerations. One view was that the con-
cept of ‘full independence’ was meaningless, given
that no researchers are independent of their own
preconceptions or the need to have their research
funded. As a result, it was mistaken to distinguish
between industry researchers and academics who
erroneously considered themselves to be indepen-
dent. A contrary view argued that epidemiologists
and occupational health practitioners have well
recognised ethical obligations to strive for full pro-
fessional independence in research [21]. The fact
that there are, in practice, threats to researcher inde-
pendence should not be mistaken for a normative
view of the absence of independence or one that
renders all threats to independence as equivalent.
For example, the presence of a direct commercial
interest in the outcome of a study, through funding
or employment relationships, was viewed as of a
qualitatively different nature from the kinds of inter-
ests that a publicly funded researcher might hold.
To say that is not to say that all research by industry
or industry-funded researchers is problematic or
unethical, only to recognize that there are additional
ethical challenges.
8) Concerns were expressed that, in accepting data
from experimental human volunteer studies, regula-
tors were generating a market for such studies,
which will create a climate which encourages cutting
of ethical corners. In discussing this scenario, the
group was unable to achieve a consensus in its ana-
lysis. While there was agreement that the role of all
scientists involved was to be vigilant about opportu-
nistic pressures applied to researchers, and to consis-
tently uphold ethical requirements in research, there
was disagreement as to how likely this scenario was,
at least in the developed world. Moreover, within
the group, there was a concern that pressure to
secure ethical approval from private sector ethical
review organisations would be likely to escalate. This
position was not arguing that all human studies are
a product of this cutting of corners, but for greater
concern about this possibility.
9) Lastly, a perspective was advanced that any
experimental studies performed with human volun-
teers for purposes of generating information to
inform a reference value should be assumed to be
unethical as the default position, until the research-
ers can provide a coherent case as to why it would
be ethically justified in taking into account foreseen
health benefits and risks/hazards involved. An alter-
native view was that such studies were not inher-
ently different from other human experimental
studies with pesticides and that the same criteria
should be applied to judge their acceptability.
Conclusion
All ethical guidelines converge on the position that any
research on pesticides involving human subjects must
be conducted such that the human dignity, integrity,
health, autonomy and fundamental freedoms of the par-
ticipants are respected and protected. The extent to
which such provisions can be protected in the context
of experimental studies involving human exposure to
pesticides remains contested. While the workgroup
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also significant differences that could not be reconciled.
Nonetheless, we have proposed in this manuscript var-
ious principles and criteria that may help in making the
difficult ethical decisions that are required, but have also
outlined some of the more intractable differences of opi-
nion which are inevitable in matters of ethical analysis,
and which we propose should form a basis for further
debates and guidelines to achieve better resolution of
this matter.
Appendix
National Research Council recommendations regarding
acceptance of data from human volunteer studies for
pesticide registration [28]
￿ The study is necessary and scientifically valid - that
is, it addresses an important regulatory question that
cannot be answered with animal studies or observa-
tional studies involving human subjects and has
been designed, conducted, and reported in a manner
that ensures the study will be adequate scientifically
to answer the question.
￿ The societal benefits of the study outweigh any
anticipated risks to participants.
￿ Intentional human dosing studies that are to be
used only to improve the accuracy of a reference
dose (RfD), and that otherwise provide no health or
environmental benefit, can be justified only when
t h e r ei sr e a s o n a b l ec e r t a i n ty that participants will
experience no adverse effects.
￿ All of the recognized ethical standards and proce-
dures for protecting the interests of study partici-
pants are observed, including equitable selection
and recruitment of participants, informed consent,
and independent review of the scientific and ethical
merits of the study by an Institutional Review Board
(IRB) or its foreign equivalent.
Additional material
Additional file 1: Paper Evaluation Sheet. This file includes the data
capture tool used for reviewing experimental studies involving human
exposure to pesticides.
Additional file 2: An ethical analysis: use of data from human
volunteer studies involving exposure to pesticides. This file includes
a detailed exposition of the ethical analysis in assessing the ethical basis
for experimental studies involving human exposure to pesticides.
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